Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pravastatin or Pentoxifylline/Tocopherol for Prevention of Radiation-Induced Lymphedema/Fibrosis
NCT06494111Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2025
- Primary completion
- May 2029
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pravastatin, pentoxifylline and tocopherol in lymphedema and fibrosis (3 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Safety and adverse events at 1 year. Started Feb 2025; status: recruiting.
02
Drugs
pravastatinpentoxifyllinetocopherol
03
Conditions
lymphedemafibrosis
Beyond the preview
Go deeper on NCT06494111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06494111.